Author + information
- Jean-François Sarrazin, MD⁎ (, )
- François Philippon, MD,
- Jean Guimond, MD,
- Michel Tessier, MD and
- Mikaël Trottier, MD
- ↵⁎Institut universitaire de cardiologie et pneumologie de Québec, 2725, chemin Sainte-Foy, Québec G1V 4G5, Canada
We thank Drs. Beck and Dickfield for their interest in our paper (1) and their additional contribution to this topic with their new data.
In their letter to the editor, they reported their data on 69 patients with remote implantable cardioverter-defibrillator implantation and no clinical evidence of device infection, who all underwent fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography before ventricular tachycardia ablation. They found no significant 18F-FDG uptake around the generator or leads in these patients, confirming the absence of abnormalities in the control group and the usefulness of this technology for ruling out cardiovascular implantable electronic device infection. Indeed, we think that this information strengthens the data from our small control group. More studies are still required to determine possible causes for false-positive and false-negatives cases.
- American College of Cardiology Foundation